Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12759795 | 0.81 | NPSR1 (0.38) | NPSR1CHRM1 | |
| SCHEMBL5930722 | 0.76 | NPSR1 (0.37) | NPSR1CHRM1 | |
| SCHEMBL12759904 | 0.76 | HSD11B1 (0.36) | NPSR1CHRM1 | |
| SCHEMBL8280788 | 0.76 | CYP4F2 (0.42) | NPSR1 | |
| SCHEMBL23369954 | 0.75 | CHRM1 (0.38) | NPSR1CHRM1 | |
| SCHEMBL12759912 | 0.74 | NPSR1 (0.33) | NPSR1CHRM1 | |
| SCHEMBL24906929 | 0.72 | NPSR1 (0.36) | NPSR1CHRM1 | |
| SCHEMBL22233967 | 0.71 | CYP3A4 (0.47) | CHRM1 | |
| SCHEMBL16700329 | 0.71 | CHRM1 (0.38) | NPSR1CHRM1 | |
| SCHEMBL17317812 | 0.70 | CHRM1 (0.40) | NPSR1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243302-A1 | BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME CORPORATION (US) | 2014-08-28 | — | — | US | disclosed |
| EP-2723737-A1 | BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | Kyorin Pharmaceutical Co., Ltd. (JP) | 2014-04-30 | — | — | EP | disclosed |
| WO-2013003383-A1 | BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2013-01-03 | — | — | WO | disclosed |
| WO-2013003383-A1 | BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2013-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243302-A1 | BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | PAICS, SBDS, SORD | NPSR1 3881/4885CHRM1 4556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.